Advancing treatments for rare diseases is often defined by scientific progress. However, a patient advocacy event hosted by CARBOGEN AMCIS in collaboration with Amicus Therapeutics highlighted an equally important factor: listening to patients.
The event brought together patients, clinicians and industry experts to share experiences and raise awareness of the realities of living with a rare disease.
From isolation to connection
For many patients, a rare disease diagnosis comes with uncertainty and limited information. As highlighted during the event, simply connecting with others who understand that journey can be both reassuring and empowering. Increasing visibility is key to ensuring rare diseases are better recognised and understood.
Linking science to real-world impact
The discussions also reinforced the importance of connecting pharmaceutical development with patient experience.
Hearing directly from patients provides valuable perspective, helping those involved in manufacturing and development better understand the real-world impact of their work.
Watch the event highlights
Watch the video on the CARBOGEN AMCIS website to hear directly from participants at the event.
Driving progress through partnership
Collaboration between CARBOGEN AMCIS and Amicus Therapeutics reflects the role partnerships play in advancing rare disease treatments.
As a global CDMO supporting drug development through to commercial manufacturing, CARBOGEN AMCIS helps bring innovative therapies closer to patients. The event served as a reminder that meaningful progress depends not only on scientific advancement, but also on listening to the patient voice.
